Free Trial
NASDAQ:CELU

Celularity (CELU) Stock Price, News & Analysis

Celularity logo
$1.44
+0.06 (+4.35%)
(As of 11/1/2024 ET)

About Celularity Stock (NASDAQ:CELU)

Key Stats

Today's Range
$1.36
$1.58
50-Day Range
$1.38
$3.08
52-Week Range
$1.30
$7.97
Volume
38,219 shs
Average Volume
98,293 shs
Market Capitalization
$31.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Celularity Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
1st Percentile Overall Score

CELU MarketRank™: 

Celularity scored higher than 1% of companies evaluated by MarketBeat, and ranked 975th out of 976 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Percentage of Shares Shorted

    6.35% of the float of Celularity has been sold short.
  • Short Interest Ratio / Days to Cover

    Celularity has a short interest ratio ("days to cover") of 40.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Celularity has recently increased by 0.19%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Celularity does not currently pay a dividend.

  • Dividend Growth

    Celularity does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.35% of the float of Celularity has been sold short.
  • Short Interest Ratio / Days to Cover

    Celularity has a short interest ratio ("days to cover") of 40.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Celularity has recently increased by 0.19%, indicating that investor sentiment is decreasing.
  • MarketBeat Follows

    2 people have added Celularity to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Celularity insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    20.70% of the stock of Celularity is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 19.02% of the stock of Celularity is held by institutions.

  • Read more about Celularity's insider trading history.
Receive CELU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celularity and its competitors with MarketBeat's FREE daily newsletter.

CELU Stock News Headlines

Crypto Crash Ahead? (27 Experts Weigh In)
Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!
Celularity anuncia la salida de un ejecutivo
See More Headlines

CELU Stock Analysis - Frequently Asked Questions

Celularity's stock was trading at $2.4740 on January 1st, 2024. Since then, CELU stock has decreased by 41.8% and is now trading at $1.44.
View the best growth stocks for 2024 here
.

Celularity Inc. (NASDAQ:CELU) announced its earnings results on Wednesday, October, 16th. The company reported ($1.03) earnings per share (EPS) for the quarter. The business had revenue of $14.68 million for the quarter. Celularity had a negative net margin of 460.34% and a positive trailing twelve-month return on equity of 65.58%.

Shares of Celularity reverse split on the morning of Thursday, February 29th 2024. The 1-10 reverse split was announced on Thursday, February 29th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of CELU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Celularity investors own include NVIDIA (NVDA), Meta Platforms (META), Lovesac (LOVE), MannKind (MNKD), PayPal (PYPL), Tesla (TSLA) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
10/16/2024
Today
11/01/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
1/07/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CELU
Fax
N/A
Employees
220
Year Founded
N/A

Profitability

Net Income
$-196,290,000.00
Net Margins
-460.34%
Pretax Margin
-460.31%

Debt

Sales & Book Value

Annual Sales
$22.77 million
Cash Flow
$6.86 per share
Book Value
$2.11 per share

Miscellaneous

Free Float
17,434,000
Market Cap
$31.67 million
Optionable
Optionable
Beta
0.44
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NASDAQ:CELU) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners